Zobrazeno 1 - 10 of 245 pro vyhledávání: '"Proia TA"'
1
Akademický článek
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.
Autor: Vasalou C; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Proia TA; Translational Medicine, Waltham, Massachusetts, USA., Kazlauskas L; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Przybyla A; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Sung M; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Mamidi S; AstraZeneca Research & Development, Cambridge, UK., Maratea K; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Griffin M; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Sargeant R; Clinical Pharmacology & Safety Sciences, Cambridge, UK., Urosevic J; AstraZeneca Research & Development, Cambridge, UK., Rosenbaum AI; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, South San Francisco, California, USA., Yuan J; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, South San Francisco, California, USA., Aluri KC; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Ramsden D; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Hariparsad N; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Jones RDO; AstraZeneca Research & Development, Cambridge, UK., Mettetal JT; AstraZeneca Research & Development, Waltham, Massachusetts, USA.
Publikováno v: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jun; Vol. 13 (6), pp. 994-1005. Date of Electronic Publication: 2024 Mar 26.
Zobrazit plný text záznamu
2
Akademický článek
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
Autor: Pore N; AstraZeneca, Gaithersburg, Maryland., Wu S; AstraZeneca, Gaithersburg, Maryland., Standifer N; AstraZeneca, Gaithersburg, Maryland., Jure-Kunkel M; AstraZeneca, Gaithersburg, Maryland., de Los Reyes M; AstraZeneca, Gaithersburg, Maryland., Shrestha Y; AstraZeneca, Gaithersburg, Maryland., Halpin R; AstraZeneca, Gaithersburg, Maryland., Rothstein R; AstraZeneca, Gaithersburg, Maryland., Mulgrew K; AstraZeneca, Gaithersburg, Maryland., Blackmore S; AstraZeneca, Gaithersburg, Maryland., Martin P; AstraZeneca, Gaithersburg, Maryland., Meekin J 3rd; AstraZeneca, Gaithersburg, Maryland., Griffin M; AstraZeneca, Waltham, Massachusetts., Bisha I; AstraZeneca, Munich, Germany., Proia TA; AstraZeneca, Waltham, Massachusetts., Miragaia RJ; AstraZeneca, Cambridge, United Kingdom., Herbst R; AstraZeneca, Gaithersburg, Maryland., Gupta A; AstraZeneca, Gaithersburg, Maryland., Abdullah SE; AstraZeneca, Gaithersburg, Maryland., Raja R; AstraZeneca, Gaithersburg, Maryland., Frigault MM; AstraZeneca, Gaithersburg, Maryland., Barrett JC; AstraZeneca, Gaithersburg, Maryland., Dennis PA; AstraZeneca, Gaithersburg, Maryland., Ascierto ML; AstraZeneca, Gaithersburg, Maryland. ml.ascierto@gmailcom michael.oberst@astrazeneca.com., Oberst MD; AstraZeneca, Gaithersburg, Maryland. ml.ascierto@gmailcom michael.oberst@astrazeneca.com.
Publikováno v: Cancer discovery [Cancer Discov] 2021 Nov; Vol. 11 (11), pp. 2828-2845. Date of Electronic Publication: 2021 Jul 06.
Zobrazit plný text záznamu
3
Akademický článek
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.
Autor: Carnevalli LS; Bioscience, Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom. Larissa.Carnevalli@astrazeneca.com Simon.T.Barry@astrazeneca.com., Taylor MA; Bioscience, Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., King M; Bioscience, Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., Coenen-Stass AML; Translational Medicine, Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., Hughes AM; Bioscience, Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., Bell S; Bioscience, Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., Proia TA; Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Wang Y; Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Ramos-Montoya A; Bioscience, Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., Wali N; Bioscience, Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., Carroll D; Translational Medicine, Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., Singh M; Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Moschetta M; Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gutierrez PM; DMPK, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom., Gardelli C; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden., Critchlow SE; Bioscience, Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., Klinowska T; Late Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Fawell SE; Early Oncology, R&D, AstraZeneca, Waltham, United States., Barry ST; Bioscience, Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom. Larissa.Carnevalli@astrazeneca.com Simon.T.Barry@astrazeneca.com.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Jun; Vol. 20 (6), pp. 1080-1091. Date of Electronic Publication: 2021 Mar 30.
Zobrazit plný text záznamu
4
Akademický článek
METTL14 suppresses the expression of YAP1 and the stemness of triple-negative breast cancer.
Autor: Bai, Xupeng1 (AUTHOR) xupeng.bai@zju.edu.cn, Liu, Jiarui2 (AUTHOR), Zhou, Shujie2 (AUTHOR), Wu, Lingzhi1 (AUTHOR), Feng, Xiaojie3 (AUTHOR), Zhang, Pumin1,2,4 (AUTHOR) pzhangbcm@zju.edu.cn
Publikováno v: Journal of Experimental & Clinical Cancer Research (17569966). 11/20/2024, Vol. 43, p1-22. 22p.
Zobrazit plný text záznamu
5
Akademický článek
Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer.
Autor: Xie, Qi1 (AUTHOR), Liu, Xiaolin1 (AUTHOR), Liu, Rengyun2 (AUTHOR), Pan, Jingxuan3 (AUTHOR) panjx2@mail.sysu.edu.cn, Liang, Jing1 (AUTHOR) liangjing0531@163.com
Publikováno v: Molecular Cancer. 11/12/2024, Vol. 23 Issue 1, p1-37. 37p.
Zobrazit plný text záznamu
6
Akademický článek
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Autor: Proia TA; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Singh M; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Woessner R; Blueprint Medicines, Cambridge, Massachusetts., Carnevalli L; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Bommakanti G; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Magiera L; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Srinivasan S; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Grosskurth S; AbbVie, Lake County, Illinois., Collins M; Tufts University Graduate School of Biomedical Sciences, Medford, Massachusetts., Womack C; Womack Consulting, Stamford, UK., Griffin M; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Ye M; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Cantin S; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Russell D; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Xie M; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Hughes A; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Deng N; GSK, Cambridge, Massachusetts., Mele DA; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fawell S; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Barry S; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Reimer C; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Barrett JC; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., McCoon P; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts. patricia.mccoon@astrazeneca.com.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Dec 01; Vol. 26 (23), pp. 6335-6349. Date of Electronic Publication: 2020 Sep 17.
Zobrazit plný text záznamu
7
Akademický článek
The effect of BRCA1/2 mutation on breast cancer and its impact on PARP inhibitor treatments: Differential expression genes approach.
Autor: Paramita, Rafika Indah1,2,3, Panigoro, Sonar Soni4,5 sonar.soni@ui.ac.id, Wanandi, Septelia Inawati4,6,7 septelia.inawati@ui.ac.id, Fadilah, Fadilah2,3,4
Publikováno v: Journal of Applied Pharmaceutical Science. Aug2024, Vol. 14 Issue 8, p131-141. 11p.
Zobrazit plný text záznamu
8
Akademický článek
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Autor: Lin, Hao1,2,3 (AUTHOR), Liu, Chaxian1,2,3 (AUTHOR), Hu, Ankang1,2,3 (AUTHOR), Zhang, Duanwu4 (AUTHOR) duanwu@fudan.edu.cn, Yang, Hui1,2,3,5,6 (AUTHOR) hui_yang@fudan.edu.cn, Mao, Ying1,2,3,6 (AUTHOR) maoying@fudan.edu.cn
Publikováno v: Journal of Hematology & Oncology. 5/8/2024, Vol. 17 Issue 1, p1-81. 81p.
Zobrazit plný text záznamu
9
Akademický článek
Integrating spatial transcriptomics and single-cell RNA-sequencing reveals the alterations in epithelial cells during nodular formation in benign prostatic hyperplasia.
Autor: Fei, Xiawei1 (AUTHOR), Liu, Jican2 (AUTHOR), Xu, Junyan3,4 (AUTHOR), Jing, Hongyan2 (AUTHOR), Cai, Zhonglin4 (AUTHOR), Yan, Jiasheng4 (AUTHOR), Wu, Zhenqi1 (AUTHOR), Li, Huifeng1 (AUTHOR) urologylihf1301@sina.com, Wang, Zhong4 (AUTHOR) zhongwang2010@sina.com, Shen, Yanting4,5 (AUTHOR) shenyanting798@126.com
Publikováno v: Journal of Translational Medicine. 4/23/2024, Vol. 22 Issue 1, p1-15. 15p.
Zobrazit plný text záznamu
10
Akademický článek
Emerging mechanisms of the unfolded protein response in therapeutic resistance: from chemotherapy to Immunotherapy.
Autor: He, Jiang1,2,3,4,5 (AUTHOR) hj2008s@csu.edu.cn, Zhou, You6 (AUTHOR), Sun, Lunquan1,2,3,4,5 (AUTHOR) lunquansun@csu.edu.cn
Publikováno v: Cell Communication & Signaling. 1/31/2024, Vol. 22, p1-22. 22p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje